These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22009273)

  • 1. [The neuropsychology of nigrostriatal dopaminergic transmission in Parkinson's disease].
    Wallesch C
    Fortschr Neurol Psychiatr; 2011 Dec; 79(12):692-5. PubMed ID: 22009273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopaminergic activation of Fos and the rat model of Parkinson's disease.
    Cole DG
    Adv Neurol; 1993; 60():334-7. PubMed ID: 8380526
    [No Abstract]   [Full Text] [Related]  

  • 4. Striatal dysfunction increases basal ganglia output during motor cortex activation in parkinsonian rats.
    Belluscio MA; Riquelme LA; Murer MG
    Eur J Neurosci; 2007 May; 25(9):2791-804. PubMed ID: 17561844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Movement disorders and basal ganglia function].
    Dietrichs E
    Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1968-71. PubMed ID: 18787574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
    Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nigrostriatal system in Parkinson's disease.
    Graybiel AM; Hirsch EC; Agid Y
    Adv Neurol; 1990; 53():17-29. PubMed ID: 1978514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of repetitive and nonrepetitive sequential arm movements in patients with Parkinson's disease.
    Agostino R; Berardelli A; Formica A; Stocchi F; Accornero N; Manfredi M
    Mov Disord; 1994 May; 9(3):311-4. PubMed ID: 8041371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease.
    Anglade P; Tsuji S; Javoy-Agid F; Agid Y; Hirsch EC
    Ann Neurol; 1995 Feb; 37(2):265-72. PubMed ID: 7847868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of neostriatal and mesostriatal or mesolimbic dopaminergic fibres in Parkinson's disease with and without dementia: prospects, concepts and facts.
    Cools AR
    Yakubutsu Seishin Kodo; 1990 Mar; 10(1):15-34. PubMed ID: 2220127
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
    Melamed E; Hefti F
    Adv Neurol; 1984; 40():149-57. PubMed ID: 6695591
    [No Abstract]   [Full Text] [Related]  

  • 13. Perturbation of a prehension movement in Parkinson's disease.
    Scarpa M; Castiello U
    Mov Disord; 1994 Jul; 9(4):415-25. PubMed ID: 7969208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal ganglia and Parkinson's disease: neurobiological and pharmacological aspects in animals and man.
    Cools AR
    Clin Neurol Neurosurg; 1984; 86(3):178-95. PubMed ID: 6091966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O
    Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Functional mapping of dopaminergic transmission].
    Sawamoto N
    Rinsho Shinkeigaku; 2007 Nov; 47(11):832-4. PubMed ID: 18210810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

  • 20. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease.
    Dluzen DE; McDermott JL
    J Gend Specif Med; 2000; 3(6):36-42. PubMed ID: 11253381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.